Eli Chapman, PhD

Associate Professor, Pharmacology and Toxicology
Associate Professor, Drug Discovery & Development (DDD)

The Chapman lab is a chemical biology lab. They are primarily focused on finding synthetic small molecules or natural probes and leads through targeted approaches, on understanding the mechanisms and modes of action of these molecules, and on improving the molecules through medicinal chemistry. We use contemporary molecular biology and protein biochemistry procedures to produce the desired target proteins and then develop assays amenable to moderate to high throughput screening. Through development, we use cellular amenable to understand the modes of action, biophysics to understand the mechanisms of action, structural biology to guide molecular improvements, and synthetic chemistry to optimize hit compounds. We often simultaneously probe families of enzymes in a parallel fashion in an effort to pre-program specificity, mitigating downstream off-target liabilities and aiding development. Currently, we have several programs in the lab including antibiotics targeting bacterial HSP60 (GroEL); anti-cancer targeting specific HSP70s, elF4A, and NRF2; and anti-type 2 diabetes targeting PTP1B. 

View UA Profile

Education & Post Graduate Training: 

BS, Chemistry, University of California at Berkeley, 1996
MA, Chemistry, Columbia University (New York), 1998
PhD, Chemistry, Scripps Research Institute (California), 2003

Select Publications

2021

Sivinski J, Ambrose AJ, Panfilenko I, et al. "Functional Differences between E. coli and ESKAPE Pathogen GroES/GroEL." mBio. 2021;12(1). PMCID: PMC7844535  PMID: 33436430
Schmidlin CJ, Tian W, Dodson M, Chapman E, Zhang DD. "FAM129B-dependent activation of NRF2 promotes an invasive phenotype in BRAF mutant melanoma cells." Mol Carcinog. 2021;60(5):331-341. PMCID: PMC8189631  PMID: 33684228
Liu P, Dodson M, Li H, et al. "Non-canonical NRF2 activation promotes a pro-diabetic shift in hepatic glucose metabolism." Mol Metab. 2021;51:101243. PMCID: PMC8164084  PMID: 33933676
Ray A-M, Salim N, Stevens M, et al. "Exploiting the HSP60/10 chaperonin system as a chemotherapeutic target for colorectal cancer." Bioorg Med Chem. 2021;40:116129. PMCID: PMC8194340  PMID: 33971488
Jennings EQ, Ray JD, Zerio CJ, et al. "Sirtuin 2 Regulates Protein LactoylLys Modifications." Chembiochem. 2021;22(12):2102-2106. PMCID: PMC8205944  PMID: 33725370
Ambrose AJ, Chapman E. "Function, Therapeutic Potential, and Inhibition of Hsp70 Chaperones." J Med Chem. 2021;64(11):7060-7082. PMID: 34009983
Schmidlin CJ, Shakya A, Dodson M, Chapman E, Zhang DD. "The intricacies of NRF2 regulation in cancer." Semin Cancer Biol. 2021. PMID: 34020028
Liu P, Luo G, Dodson M, et al. "The NRF2-LOC344887 signaling axis suppresses pulmonary fibrosis." Redox Biol. 2021;38:101766. PMCID: PMC7573654  PMID: 33126057

2020

Branco PC, Pontes CA, Rezende-Teixeira P, et al. "Survivin modulation in the antimelanoma activity of prodiginines." Eur J Pharmacol. 2020;888:173465. PMID: 32814079
Liu P, Dodson M, Fang D, Chapman E, Zhang DD. "NRF2 negatively regulates primary ciliogenesis and hedgehog signaling." PLoS Biol. 2020;18(2):e3000620. PMCID: PMC7043785  PMID: 32053600